Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA

Molecular Therapy Nucleic Acids

Volumn 4, Issue 6, 2015, Pages e245-

  Grondin, Richard ^a   Ge, Pei ^b   Chen, Qingmin ^b   Sutherland, Jessica E ^b   Zhang, Zhiming ^a   Gash, Don M ^a   Stiles, David K ^c   Stewart, Gregory R ^c   Sah, Dinah W Y ^b   Kaemmerer, William F ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

Convection enhanced delivery; Huntington's disease; Putamen; Rhesus; SiRNA

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; HUNTINGTIN; SMALL INTERFERING RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; COS 7 CELL LINE; FEMALE; FLOW RATE; GENE REPRESSION; HELA CELL LINE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; RNA ISOLATION;

EID: 84943425235     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.20     Document Type: Article

References (15)

1. Persichetti, F, Srinidhi, J, Kanaley, L, Ge, P, Myers, RH, D'Arrigo, K et al. (1994). Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Dis 1: 159-166.
2. van Bilsen, PH, Jaspers, L, Lombardi, MS, Odekerken, JC, Burright, EN and Kaemmerer, WF (2008). Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 19: 710-719.
3. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
4. Drouet, V, Perrin, V, Hassig, R, Dufour, N, Auregan, G, Alves, S et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65: 276-285.
5. Grondin, R, Kaytor, MD, Ai, Y, Nelson, PT, Thakker, DR, Heisel, J et al. (2012). Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135(Pt 4): 1197-1209.
6. McBride, JL, Pitzer, MR, Boudreau, RL, Dufour, B, Hobbs, T, Ojeda, SR et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19: 2152-2162.
7. Stiles, DK, Zhang, Z, Ge, P, Nelson, B, Grondin, R, Ai, Y et al. (2012). Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233: 463-471.
8. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
9. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825.
10. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044.
11. Machida, Y, Okada, T, Kurosawa, M, Oyama, F, Ozawa, K and Nukina, N (2006). rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 343: 190-197.
12. Rodriguez-Lebron, E, Denovan-Wright, EM, Nash, K, Lewin, AS and Mandel, RJ (2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12: 618-633.
13. Lu, XH and Yang, XW (2012). "Huntingtin holiday": progress toward an antisense therapy for Huntington's disease. Neuron 74: 964-966.
14. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
15. Tukey, JW (1949). Comparing individual means in the analysis of variance. Biometrics 5: 99-114.